| You are here: Home: BCU Surgeons 2004 Vol 3 Issue 1: Anthony Howell, MD, MSc, FRCP: Select publications
Select Publications
Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003; http://www.abstracts2view.com/bcs03/search.php?query=Boccardo&where[]=authors&search=do.
Dowsett M, on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;Abstract 4.
Dowsett M, on behalf of the IMPACT Trialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: The IMPACT trial. Breast Cancer Res Treat 2003;Abstract 1.
Dowsett M, on behalf of the IMPACT Trialists. Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) than with tamoxifen (T) or anastrozole plus tamoxifen (C) in the IMPACT trial: A potential predictor of relapse-free survival. Breast Cancer Res Treat 2003;Abstract 2.
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
|
